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Abstract 
Background: Artemisinin (ART) is an efficacious and safe anti-malarial drugs but has low oral bioavailability and 
auto-induction profiles during multiple dosing. The pharmacokinetic disadvantages have been found to partially 
depend on the induction of cytochrome P-450 enzymes by ART and resulted in the therapeutic failure due to insuffi-
cient drug levels. The present study, therefore, investigated the impacts of chrysosplenetin (CHR), a polymethoxylated 
flavonoid from Artemisia annua, on the pharmacokinetics and the anti-malarial efficacy of ART against Plasmodium 
berghei. The inhibition of CHR on enzymatic activity of CYP1A2, CYP2A, CYP2C19, CYP2D6, CYP2E1, and CYP3A in rat 
liver microsome was also investigated. IC50, Km, Ki, and inhibitory type of CHR were respectively calculated.
Methods: Twenty rats were randomly divided into four groups and received three-day oral doses of ART in absence 
or presence of CHR (in ratio of 1:0, 1:1, 1:2, and 1:4, respectively). Plasma samples were separately harvested for ART 
pharmacokinetics analysis using a valid liquid chromatography tandem mass spectrometric (LC–MS/MS) method. 
Female Kunming mice were inoculated by P. berghei K173 strain and pre-exposed to three-day oral administration of 
ART with or without CHR as pharmacokinetics protocol. Giemsa staining method was applied to calculate percent 
parasitaemia (%) and inhibition (%). In vitro rat liver microsomal model was employed to elucidate the inhibitory 
effect of CHR on CYP1A2, CYP2A, CYP2C19, CYP2D6, CYP2E1, and CYP3A.
Results: The AUC0–t, Cmax, and t1/2 of ART increased significantly (P < 0.05 or P < 0.01) as well as declined CLz (P < 0.05 
or P < 0.01) after three-day oral doses of ART in presence of CHR (1:2) when compared with ART alone. Also, parasi-
taemia (%) remarkably attenuated 1.59 folds with 1.63-fold augmented inhibition (%) when the ratio between ART 
and CHR reached 1:2. CHR itself had no anti-malarial efficacy (P > 0.05). CHR inhibited in vitro activity of CYP1A2 and 
CYP2C19 (P < 0.01, IC50 = 4.61 and 6.23 μM) in a concentration–response manner. The inhibition did not emerge on 
CYP2E1 and CYP3A until the CHR concentration exceeded 4.0 μM (P < 0.01, IC50 = 28.17 and 3.38 µM). CHR has no 
impact on CYP 2A and CYP2D6 (P > 0.05). The inhibition types of CHR on CYP1A2 and CYP3A belonged to noncom-
petitive and uncompetitive, respectively.
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Background
Artemisinins (ART) (Fig.  1a) anti-malarial drugs belong 
to the sesquiterpene lactone family containing the spe-
cific endoperoxide bridge. They have been successfully 
used for more than two decades in the clinical treat-
ment of malaria in regions with multi-drug resistant 
Plasmodium falciparum [1]. Up to now, ART and its 
semisynthetic derivatives are still the most important 
anti-malarial drugs available and ART-based combi-
nation therapy (ACT) has been recommended world-
wide as first-line treatment for falciparum malaria since 
2006 [2, 3]. Despite its widespread use, ART has very 
unusual pharmacokinetic properties with saturable 
first-pass hepatic metabolism and time-dependent phar-
macokinetics during repeated oral administration [4–6]. 
ART, therefore, has very low oral bioavailability, merely 
8–10 %. The auto-induction of both phase I and phase II 
metabolism of ART was demonstrated to be present in 
healthy Chinese subjects after a recommended two-day 
oral dose of ART-piperaquine probably due to the induc-
tion of CYP2B6 and CYP3A4 enzyme activity [7]. It was 
reported that ART in  vitro metabolism was mediated 
primarily by CYP2B6, with a minor contribution from 
CYP2A6 and CYP3A4 [8]. El-Lakkany et  al. [9] found 
that coadministration of grapefruit juice with artemether 
(150  mg/kg) eliminated eggs and granulomatous reac-
tions and achieved complete protection of the host from 
damage induced by schistosomal infection because of the 
inhibitory effects of grapefruit juice on CYP450 and cyt 
b5.
Conclusions: Co-administration of ART with CHR in ratio of 1:2 achieved a synergic anti-malarial effect partly 
because of the noncompetitive or uncompetitive inhibition of CHR of drug-metabolism enzymes, especially CYP3A 
which is closely related to the auto-induction of ART.
Keywords: Chrysosplenetin, Artemisinin, Pharmacokinetics, Anti-malarial efficacy, Rat liver microsome, CYP3A
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c
Fig. 1 Structure of ART (a), ARM (b), and CHR (c)
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Literature has shown that several polymethoxyfla-
vonoid constituents from Artemisia annua, such as 
artemetin, casticin, chrysosplenetin (CHR, Fig.  1c) and 
chrysosplenol D may contribute to the activity of ART 
against P. falciparum [10, 11]. However, the mechanism 
of action has not yet been well defined. Generally, most 
flavonoids have an inhibitory effect on CYP450 enzymes 
and the aglycones have a stronger inhibition than glyco-
sides [12, 13]. CHR has been previously enriched from the 
industrial wastes of ART about 1 g (over 98 % purity) and 
a China National Invention Patent (ZL201210093926.0, 
China) has been awarded. Structure of CHR was identi-
fied by 1H-NMR, 13C-NMR and 2D-NMR [14–19]. The 
present study was designed to investigate the impact of 
CHR on the pharmacokinetics and the anti-malarial effi-
cacy of ART against Plasmodium berghei. Further, the 
inhibition of CHR on in vitro CYP450 enzymatic activity 
was also elucidated. It was demonstrated here that CHR 
increased the AUC, Cmax, and t1/2 of ART along with a 
decreased CLz and enhanced its in vivo anti-malarial effi-
cacy against malarial parasites infection, partially due to 
the uncompetitive inhibition on CYP3A. The data pre-
sented in this paper indicate the promising tendency for 
CHR to be used as CYP 450 enzymatic inhibitor in coor-
dination with ART-type anti-malarial drugs.
Methods
Chemicals and reagents
Artemisinin and internal standard artemether (ARM, 
Fig. 1b) were purchased from Chongqing Huali Konggu 
Co., Ltd. (purity >99.0  %, Chongqing, China). CHR 
(purity >98.0  %) was previously isolated and purified 
from the industrial wastes of ART (acetone layer) with 
about 1  % yield in the authors’ laboratory. Industrial 
waste was kindly gifted by Chongqing Huali Konggu Co. 
Ltd, and the voucher specimen of the waste has been 
deposited in the College of Pharmacy, Ningxia Medical 
University, for further references.
Six metabolic probes including phenacetin (PN), cou-
marin (CA), omeprazole (OMP), dextromethophan 
(DM), and chlorzoxazone (CLZ) were purchased from 
National Institutes for Food and Drug Control, China. 
Midazolam (MDZ) injection was provided by Jiangsu 
Enhua Pharmaceutical Co., Ltd (10 mg/2 mL). NADPH, 
EDTA, BCA kit, DTT, and Tris were of analytical grade 
and purchased locally. Acetonitrile and methanol (HPLC 
grade) were purchased from Fisher Chemicals (Fairlawn, 
NJ, USA).
Rat liver microsomes (RLM, Sprague–Dawley) were 
purchased from Wuhan Pulaite Medical and Technical 
Co. Ltd (M10011). Protein concentration was determined 
as 20 mg/mL by bicinchoninic acid (BCA) method using 
bovine serum albumin as standard.
Instrumentation
The LC system for LC–MS/MS was Shimadzu Nexera 
UPLC LC-30A containing a binary LC-30AD pump, 
DGU-20A5 vacuum degasser, SIL-30AC autosampler 
and CTO-30A thermostat column compartment. An API 
4000 triple quadrupole mass spectrometer (AB SCIEX, 
Foster, USA) with an electrospray ionization (ESI) oper-
ated in the positive ion mode was used for analysis. 
Quantification was performed using multiple reaction 
monitoring (MRM) for the transitions m/z 300. 1–209.0 
for ARN and 316.2–163.0 for ARM (Fig. 2). The system 
was controlled by Analyst software version 1.5.1. Separa-
tion was performed on a Shimadzu XR-ODS C18 column 
(2.0 mm × 100 mm, 2.2 µm) with a Shimadzu ODS C18 
security guard column (5 mm × 2.0 mm, 2.2 µm) main-
tained at 30 °C using a mobile phase containing acetoni-
trile and 0.1 % formic acid in 10 mM ammonium acetate 
(85:15, v/v) at a flow rate of 300 µL/min. The source tem-
perature was maintained at 600  °C and the ESI source 
voltage was set at 5500  V. Collision gas pressure was 3 
units and collision energy was 17 V.
The six enzymatic probe substrates were standardized 
by using Agilent 1200 (Agilent, USA) RP-HPLC sys-
tem consisted of an on-line G1322A vacuum degasser, 
a G1311A quaternary pump, a G1329A injection valve 
(USA) with a sample loop of 20 μL, a G1314B UV–visible 
diode-array detector (DAD). A phenomenex C18 column 
(Synergi Hydro-RP 80A, 150 mm × 4.6 mm, 4 μm) was 
used as stationary phase with a flow rate of 1.2 mL/min 
at 30 °C. The isocratic mobile phase consisted of acetoni-
trile and purified water containing 1 % triethylamine and 
0.02 M sodium dihydrogen phosphate (40:60 for PN, CA, 
DM, CLZ, and MDZ; 35:65 for OMP, v/v, PH = 3.5) was 
respectively used for assay of PN (wavelength: 250 nm), 
CLZ (282  nm), MDZ (230  nm), OMP (302  nm), CA 
(278 nm), and DM (202 nm).
Stock solutions of chemicals
ART and CHR were separately suspended in 0.5  % car-
boxy methyl cellulose (CMC-Na) by sufficient emulsifica-
tion to get the stock solution of 2  mg/mL strength and 
diluted to get the desired concentrations for each drug 
before it was administrated by the intramuscular injec-
tion or gavage perfusion. Master stock solutions for 
assay of blood concentration were individually prepared 
by dissolving ARN and ARM standards in acetonitrile at 
equivalent concentrations of 1000 μg/mL and were grad-
ually diluted to 2 μg/mL by mobile phase for the prepa-
ration of calibration curve (0.2–200  ng/mL) and quality 
control (QC) samples (0.5, 10 and 160 ng/mL for ART), 
respectively.
For in vitro hepatic metabolic study, CHR and six enzy-
matic probes were separately prepared in methanol to 
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strength of 1 mg/mL stock solutions and were diluted to 
desired concentrations by phosphate buffers (PBS, 0.1 M, 
PH = 7) before use. QC samples were solved in inactive 
RLM with three concentration levels (3.0, 28.0 and 89.0 
for PN; 3.4, 34.2 and 100.0 for CA; 6.0, 29.5 and 118.0 for 
CLZ; 3.0, 15.0 and 49.0 for MDZ; 2.7, 13.5 and 43.2 for 
DM). A serial of RLMs in strength of 1.25, 1, 0.75, 0.5, 
0.25  mg/mL were gained for optimization of protein 
Fig. 2 Collision-induced dissociation mass spectra for ART (a MS1 and b MS2) and ARM (c MS1 and d MS2). For experimental conditions see “Instru-
mentation”
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concentration experiment by diluting the stock protein 
solution in strength of 20 mg/mL (stored at −80 °C). All 
other stock solutions were stored at 4 °C when not in use.
Method validation
Calibration curves for artemisinin were constructed by 
weighted least-squares linear regression (1/x2) analysis 
of an eight-point calibration curve by plotting peak area 
of the analyte versus the peak area of the internal stand-
ard. The assay was validated through linearity, inter- and 
intra-day accuracy and precision, recovery, lower limits 
of quantification (LLOQ), stability, and matrix effect as 
usual.
Calibrations curves for six probe substrates in inactive 
RLM were obtained and the assay was evaluated through 
linearity, inter- and intra-day precision and accuracy, and 
recovery.
Pharmacokinetics study
Male SD rats (200–240  g) were supplied by Laboratory 
Animal Center of Ningxia Medical University (Grade II, 
Certificate No. SCXY 2011-0001). Animals were accli-
matized in environmentally controlled breeding cages 
for at least 3 days before being used and were provided 
with standard laboratory food and water and were fasted 
for 12 h prior to the study. Water was freely available for 
rats during experiments. The experimental protocol was 
approved by the University Ethics Committee. All pro-
cedures involving animals were in accordance with the 
Regulations of the Experimental Animal Administra-
tion, State Committee of Science and Technology, Peo-
ple’s Republic of China. 20 rats were randomly divided 
into 4 groups (n =  5). Group A was the control vehicle 
(ART alone) and group L, M, and H were the combina-
tion groups with CHR in three fixed ratios (1:1, 1:2, and 
1:4). The suspension of CHR was continuously adminis-
tered (each time per day) to rats in group L, M, and H by 
gavage at doses of 5, 10, 20 mg/kg for 3 days, respectively. 
Group A was orally given by 0.5  % CMC-Na solution 
once per day for 3 days. On day 3, an intramuscular injec-
tion of ART (5  mg/kg) was subsequently administered 
1 h after CHR or CMC-Na solution pre-exposure. Blood 
samples (500 µL) were collected into centrifuge tube with 
heparin at 0, 10, 20, 30, 60, 90, 120, 240, 360, 480, 600, 
720, and 1440 min from the orbit after the administration 
of ART, respectively. Two hours later, animals took food 
and water freely to replenish.
Plasma samples were separated by centrifugation 3500g 
for 10  min and 200  µL plasmas were stored at −20  °C 
until analysis. To 100 μL blank plasma, 50 μL ARM work-
ing solution (IS, 2  μg/mL), 100  μL methanol aqueous 
solution (50:50, v/v), and a standard solution or quality 
control (QC) solution were added. After vortex mixing 
for 1  min, the sample was extracted with 3  ×  3  mL of 
methyl tert-butyl ether with gentle shaking for 10 min fol-
lowed by centrifugation at 3500g for 10 min. The methyl 
tert-butyl ether extracts were combined and evaporated 
to dryness by a Pressure Gas Blowing Concentrator (mul-
tivap nitrogen evaporation system 118, Organomation 
Co., Ltd, USA) at 40  °C. The residue was reconstituted 
in 100 μL methanol and was filtered through a 0.22 µm 
nylon filter. Aliquots (10 μL) of the solution were injected 
onto the LC–MS analysis.
In vivo anti‑malarial efficacy
Female Kunming mice (18–22  g) for the experiment of 
in  vivo chemo-suppressive study were purchased from 
Animal Center in Academy of Military Medical Science 
(Grade II, Certificate No. SCXK 2002-001). Animals were 
divided into eight groups (n  =  10) including placebo 
group (normal saline only), ART alone (5  mg/kg), CHR 
alone (5, 10 and 20 mg/kg), and ART-CHR combination 
groups (1:1, 1:2, and 1:4). Two hours after being inocu-
lated, they were administrated in the same delivery route 
and the same dosage of ART and CHR as pharmacoki-
netic study.
Stocks of the malaria parasite P. berghei K173 strain 
(chloroquine sensitive) were continuously maintained 
in the Microbiology Laboratory of Academy of Military 
Medical Sciences, China, and alternately stored by liq-
uid nitrogen cryopreservation and blood subinoculation 
in mice. Approximate one million infected erythrocytes 
were inoculated into the enterocoelia of each mouse 
before use.
Twenty-four hours after the last dosing, the blood was 
collected from caudal vein of mice. Thin blood smear 
slides were air-dried, methanol-fixed, and stained in 
Giemsa for 40  min. The Giemsa-stained slides were 
examined for counting the number of parasites in ran-
dom three microscopic fields, equivalent to over 200 
erythrocytes each field at 1000× magnification. Percent 
parasitaemia (%) was calculated through dividing the 
number of total red blood cells by that of infected red 
blood cells. Percentage inhibition (%) for each drug was 
calculated relative to placebo. Reproducibility of counts 
was checked by two other readers to maintain the quality 
control.
In vitro rat liver microsome experiment
The incubation system included 40  μL of RLM (pro-
tein concentration was optimized as 1  mg/mL for PN; 
0.75  mg/mL for OPZ; 0.5  mg/mL for CA, DM, CLZ, 
and MDZ), 5 μL of substrate solution (substrate concen-
tration was optimized as 25  μM for PN; 5  μM for CA; 
20 μM for OPZ; 10 μM for DM; 15 μM for CLZ; 5 μM 
for MDZ), and NADPH-regenerating system (1.3  mM 
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NADP+, 3.3 mM G-6-P, 3.3 mM MgCl2, 4 U/mL G-6-P-
D) and a test compound (CHR, 0–50 μM). Total reaction 
volume was complemented to 200 μL by PBS. After pre-
incubating for 3 min at 37 °C, the reaction was initiated 
by the addition of NADPH solution (incubation time was 
optimized as 45 min for PN; 60 min for CA, 15 min for 
OPZ; 20 min for DM; 90 min for CLZ; 15 min for MDZ). 
200 μL ice acetonitrile was added as stop reagent. After a 
vortex for 3 min and centrifugation for 10 min at 14,000g, 
an aliquot of 20  μL supernatant was injected into the 
HPLC system at an interval of 10  min. The amount of 
methanol in diluted concentrations (<1 %) had no effect 
on liver microsomes. All the testing groups were in three 
replicates (n = 3). Under the optimized condition, Vmax, 
Michaelis constant (Km), enzyme activity (E%), and IC50 
values were obtained.
Inhibitory type determination
Incubation systems including 1.0 mg/mL RLM, PN (12.5, 
25.0, and 50.0  μM), NPDPH, and CHR (0, 2, 4, 8  μM) 
for 1A2 or 0.5  mg/mL RLM, MDZ (2.5, 5.0, 10.0  μM), 
NPDPH, and CHR (0, 2, 4, 8  μM) for CYP3A were 
employed as above (n = 3). A serial of Lineweaver–Burk 
plots by 1/[S] versus 1/V were prepared individually 
under different concentrations of CHR. The location of 
intersection point for the linear lines decided the type 
of inhibition. Namely, if the point lied in Y axis it was 
competitive inhibition and if it lied in X axis it was non-
competitive inhibition. Finally, if the linear lines were 
paralleled, it was uncompetitive inhibition. Concomi-
tantly, inhibition constant (Ki) was calculated when a 
second plotting was given by intercepts of the four lines 
versus [I] (inhibitor concentration).
Data analysis
Pharmacokinetic parameters were computed from 
plasma concentration–time profiles of ART by software 
DAS 3.0. Statistical significance of differences was ana-
lyzed by SPSS 16.0 statistical software with a significance 
level of P < 0.05 and 0.01.
Results and discussion
UPLC‑MS/MS method for ART
The electrospray ionization mass spectra for ART and 
ARM were shown in Fig. 2a (MS1 for ART), b (MS2 for 
ART), c (MS1 for ARM), and d (MS2 for ARM). Under 
optimized UPLC conditions, ART and ARM were 
eluted within 2.5 min (Fig. 3b, c). Blank plasma showed 
no significant interfering peaks at the retention times 
of each analyte (Fig.  3a). The calibration curve of ART 
was linear over the concentration range of 0.2–200.0 ng/
mL (y =  0.0336x +  0.0259, r =  0.9965, w =  1/x2) with 
LLOQ 0.2 ng/mL (RSD% = 3.91, RE% = −5 %, n = 5). 
Inter- and intra-day precision and accuracy, stability, 
recovery, and matrix effect data were showed in Table 1. 
The precision and accuracy of this method indicated that 
all coefficients of variation at each concentration level 
are below 10  %. The normalized matrix effects of ART 
at low, middle, and high concentrations were close to 
1 with a low variation in accordance with international 
guidelines [20]. ART was found stable in plasma for at 
least 6 and 24 h at ambient temperature before and after 
treatment and was also stable during three freeze/thaw 
cycles.
HPLC–UV method for six probe drugs
Six probe drugs were well analysed within 10  min by 
HPLC–UV method without interference. Standard 
curves equations of six substrates in inactive RLM were 
displayed in Table  2. Details of method validation data 
were elaborately arranged in Table  3a, b in different 
strength of QC samples.
Pharmacokinetics parameters for ART in absence 
and presence of CHR
Plasma concentration–time profiles of ART, in untreated 
rats and in pre-treated rats with different combinatory 
doses of CHR, were shown in Fig. 4a, b. Corresponding 
pharmacokinetic parameters were reported in Table  4. 
This study has demonstrated that the AUC0-t of ART in 
ART-CHR-L (1:1), ART-CHR-M (1:2), and ART-CHR-
H (1:4) groups, respectively, increased 1.44-, 1.40-, and 
1.29-fold compared with ART alone (P  <  0.01) without 
dose–response manner (P  >  0.05 among the combina-
tion groups). The Cmax in ART-CHR-L (1:1) and ART-
CHR-M (1:2) group increased 1.64- and 1.65-fold versus 
control (P < 0.05) while no increase was found in ART-
CHR-H (1:4) group. The t1/2 in ART-CHR-M (1:2) group 
enhanced 1.68 folds compared with ART alone (P < 0.05). 
It showed that oral co-administration of CHR in com-
binatory ratio of 1:2 prior to intramuscular injection of 
ART achieved a longer t1/2, a higher AUC and Cmax, and 
lower CLz than ART alone.
Synergic anti‑malarial efficacy of ART in presence of CHR
The results showed in Table  5 suggested that parasitae-
mia (%) in ART alone, ART-CHR-L, ART-CHR-M, and 
ART-CHR-H groups significantly decreased 1.59, 2.23, 
2.53, and 2.01 folds (P  <  0.05) compared with placebo, 
whereas no significance was observed when CHR was 
solely used (P > 0.05). CHR, therefore, has no anti-malar-
ial effect itself. Only in ART-CHR-M group, parasitaemia 
(%) and inhibition (%), respectively, achieved 1.59-fold 
reduction (P  <  0.05) and 1.63-fold augment compared 
with ART alone. The result completely conformed to the 
pharmacokinetics study.
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Inhibition of CHR on CYP450 enzymes
Km values for PN, CA, OPZ, DM, CLZ, and MDZ were 
calculated to be 30.88, 8.90, 24.07, 28.94, 19.97, and 
7.88 μM with Vmax 0.14, 0.12, 0.58, 0.20, 0.18, 0.81 nmol/
min/mg proteins, respectively. The working substrate 
concentrations for PN, CA, OPZ, DM, CLZ, and MDZ, 
therefore, were confirmed to be 25, 5, 20, 10, 15, and 
5 μmol L−1 (lower than Km).
Graphs showed in Fig.  5 and data in Table  6 demon-
strated that CHR has a significant inhibition (P < 0.01) on 
CYP1A2 and CYP2C19 in a concentration-dependence 
Fig. 3 Representative full-scan chromatograms of (a) blank plasma, blank plasma spiked with ART (b) and ARM (c, IS), and a study sample contain-
ing ART (d) and ARM (e) after administration for 45 min
Table 1 Method validation for quantification of ART in rat plasma
RT room temperature, Pre-T Pre-treatment, Post-T post-treatment














0.5 8.51/1.24 6.57/1.24 −4.00 −2.00 2.00 2.00 57.30 98.0/1.70
10 1.41/6.75 6.67/−1.90 3.20 −0.80 −8.20 6.80 73.30 88.0/2.70
160 2.97/7.81 6.99/0.67 −6.25 −3.00 −4.38 4.38 68.90 66.0/3.10
Table 2 Standard curves equation of  six probe substrates 
in inactive RLM
Probe substrates Calibration curves R value Linear range (μM)
PN Y = 9.486X + 0.3485 0.9999 0.5–111
CA Y = 6.730X + 0.7809 0.9999 0.7–137
OPZ Y = 4.148X + 2.1741 0.9999 0.5–141
DM Y = 24.868X + 5.1424 0.9999 0.5–54
CLZ Y = 20.918X + 1.257 0.9999 1.0–295
MDZ Y = 36.365X − 16.163 0.9999 0.8–63
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manner and enzyme activity (%) decreased from 
(21.64  ±  1.05) % to (4.05  ±  1.41) % for CYP1A2, and 
from (41.98 ±  0.35) % to (0.60 ±  0.11) % for CYP2C19 
when CHR concentration increased from 0 to 50 μM. As 
for CYP2E1, CHR had a significant inhibition in a dose–
response manner only after CHR concentration exceeded 
4 μM (P < 0.05). Most interestingly, 0.5 μM of CHR signif-
icantly increased the enzyme activity (%) of CYP3A from 
48.27 ± 0.93 (0.0 μM) to 59.44 ± 2.55 (P < 0.01), and it 
slowly decreased to 57.15 ± 0.93 (P < 0.01), 52.02 ± 3.07 
(P  >  0.05), and 51.37 ±  0.84 (P  >  0.05) after CHR con-
centration added from 1.0 to 2.0  μM. An inhibition of 
Fig. 4 Mean (±SD) plasma concentration–time profiles of ART (n = 5) in ART alone (square points), ART-CHR-L (triangular points), ART-CHR-M 
(inverted triangular points), and ART-CHR-H (diamond points). a before 2 h, b after 2 h
Table 4 Plasma concentration–time profiles of ART with or without CHR (n = 5)
Data are mean values ± SD in five rats
Significantly different from ART alone: * P < 0.05, ** P < 0.01
Significantly difference from ART-CHR-H: # P < 0.05
Ratio t1/2 (h) AUC0–t [mg/(L h)] Cmax (mg/L) CLz (L/h/kg)
ART alone 3.62 ± 0.86 390.58 ± 32.46 51.58 ± 9.47 0.013 ± 0.001
ART-CHR-L (1:1) 3.89 ± 1.93 562.20 ± 101.50** 84.76 ± 19.52* 0.009 ± 0.002*
ART-CHR-M (1:2) 6.07 ± 2.04*,# 547.68 ± 76.59** 85.22 ± 29.56* 0.009 ± 0.001**
ART-CHR-H (1:4) 3.28 ± 0.77 505.21 ± 54.88** 63.16 ± 16.50 0.010 ± 0.001**
Table 5 In vivo antimalaria pharmacodynamic effect of ART in combination with CHR
* P values of drugs in relation to placebo: P < 0.05
# P values of ART-CHR combination groups in relation to ART alone: P < 0.05
Groups Dosage (mg/kg) Parasitemia (%, n = 10) P value Inhibition (%, n = 10)
placebo ART alone
Placebo 0 22.15 ± 6.25 – –
CHR-L 5 19.74 ± 13.33 0.62 – –
CHR-M 10 17.19 ± 5.45 0.05 – –
CHR-H 20 18.32 ± 8.86 0.25 – –
ART alone 5 13.95 ± 7.89* 0.01 – 37.06
ART-CHR-L 5 (1:1) 9.95 ± 5.36* 2.73 × 10−5 0.07 55.10
ART-CHR-M 10 (1:2) 8.75 ± 4.25*,# 2.16 × 10−6 0.04 60.51#
ART-CHR-H 20 (1:4) 11.00 ± 4.98* 2.72 × 10−5 0.18 50.36
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Fig. 5 Inhibition curves of CHR on CYP450 isoforms
Table 6 Effects of CHR on cytochrome P450 isoforms in rat liver microsomes in vitro
ND no detection
Compared with control group (no CHR)
* P < 0.05,** P < 0.01
CHR/μM Enzyme activity (%)
1A2 2A 2C19 2D6 2E1 3A
0 21.64 ± 1.05 14.45 ± 8.11 41.98 ± 0.35 19.25 ± 11.87 69.82 ± 7.31 48.27 ± 4.71
0.5 21.46 ± 2.83* 12.47 ± 1.91 39.56 ± 1.35** 25.62 ± 3.56 66.93 ± 1.82 59.44 ± 2.55**
1.0 17.80 ± 3.07** 12.62 ± 1.35 38.92 ± 0.56** 12.34 ± 12.08 65.76 ± 1.72 57.15 ± 0.93**
1.5 17.93 ± 1.15** 12.92 ± 0.86 37.64 ± 2.31** 12.03 ± 6.33 63.23 ± 2.40 52.02 ± 3.07
2 17.50 ± 0.58** 11.82 ± 1.76 36.14 ± 2.19** 19.81 ± 0.64 63.22 ± 2.06 51.37 ± 0.84
4 10.96 ± 3.56** 10.94 ± 6.85 29.22 ± 1.06** 18.03 ± 4.02 58.21 ± 5.63* 32.94 ± 2.87**
6 12.99 ± 1.56** 15.03 ± 0.33 21.40 ± 3.06** 13.49 ± 10.99 58.79 ± 2.29* 37.18 ± 0.46**
8 11.72 ± 2.81** 15.12 ± 0.96 13.84 ± 0.49** 14.16 ± 7.44 56.44 ± 5.63* 29.70 ± 4.12**
10 6.89 ± 1.56** 15.82 ± 1.62 8.30 ± 1.04** ND 53.81 ± 2.02* 29.08 ± 3.76**
50 4.05 ± 1.41** 7.79 ± 0.95 0.60 ± 0.11** ND 34.62 ± 6.25* 18.27 ± 14.55**
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CHR on CYP3A subsequently (P  <  0.01) emerged after 
the concentration exceeded 4 μM as well as CYP2E1. No 
impact of CHR on CYP2A6 and CYP2D6 were found in 
this paper (P > 0.05).
IC50 values were computed to 4.61  μM for 1A2, 
6.23  μM for 2C19, 3.38  μM for 3A, and 28.17  μM for 
2E1 by GraphPad Prism 5.0 software. CHR is a moderate 
inhibitor on 1A2, 3A, and 2C19 (1 < IC50 < 10 μM) and 
a weak inhibitor on 2E1 (IC50 >10 μM) according to the 
research [21].
Inhibitory type determination for 1A2 and 3A
Figure 6a, b showed that the type of CHR as an inhibitor 
on CYP1A2 belonged to non-competitive (intersection 
point lied in X axis) and that on CYP3A was uncom-
petitive inhibition (parallel lines). Ki was determined to 
4.07 μM for CYP1A2 (y = 33.221x + 135.2, r = 0.9904) 
and 3.71  μM for CYP3A (y  =  0.5416x  +  2.012, 
r = 0.9600).
Inhibition of inhibitors on enzymes has two types, 
namely irreversible and reversible inhibition. The lat-
ter includes competitive, noncompetitive, uncompeti-
tive and mixed competitive inhibition (showed in Fig. 7). 
The dynamic characteristic of uncompetitive inhibition 
(substrate is indispensable for the inhibition) is that both 
































































Fig. 6 Inhibition types determination for 1A2 (a) and 3A (b)
Fig. 7 Diagrammatic sketches showed that the difference among uncompetitive, noncompetitive inhibition, and competitive inhibition
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increased. This type of inhibition is infrequency in sin-
gle substrate catalysis of enzyme. This study demon-
strated that CHR acted as an on uncompetitive inhibitor 
of CYP3A activity and as a non-competitive inhibitor of 
CYP1A activity. The results are in accordance with the lit-
eratures [22, 23]. Especially, the fact that CHR inhibited 
CYP3A in rat liver microsome in an uncompetitive man-
ner might be meaningful for us to partly explain why CHR 
has a partial dose-dependent manner in pharmacokinet-
ics and anti-malarial efficacy studies. More interestingly, 
initially increased enzyme activity of CYP3A under a low 
concentration of CHR treatment was observed in the 
inhibition experiment using RLM. The authors specu-
late that the phenomenon might be closely related to 
the uncompetitive inhibition type of CHR on CYP3A. 
CHR exclusively bonded to enzyme-substrate complex 
(ES) instead of enzyme itself; therefore, when inhibitor is 
added into the reaction, the equilibrium reaction will shift 
to the product generation direction, which enhances the 
production of ES complex instead. When CHR concentra-
tion is very low, ES complex may not be fully bonded. The 
surplus will continue to be decomposed to enzyme and 
product by enzymolysis. So the enzyme activity initially 
increased a little compared with the control. As CHR 
concentrations increased, however, the activity slowly 
decreased and then inhibition effect was finally observed 
due to the binding between CHR and ES complex and 
therefore the hindering of the enzymolysis. The increased 
activity might, therefore, not be activated by induction of 
CHR on CYP3A but possibly depends on the shifting of 
equilibrium reaction. Further research should be carried 
out to demonstrate the hypothesis.
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